Psoriasis
📧 Sign up to get email alerts when something new happens for Psoriasis.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2026-07-31EMA Withdrawn: Qoyvolma (ustekinumab) — Celltrion Healthcare Hungary Kft.
The EMA has withdrawn Qoyvolma (ustekinumab) from the market.
-
EMA withdrawal · 2026-07-28EMA Withdrawn: Inflectra (infliximab) — Pfizer Europe MA EEIG
The EMA has withdrawn Inflectra (infliximab) from the market.
-
CLINICAL_TRIALS withdrawal · 2026-03-17Clinical Trial Update: Koebner's Phenomenon in Psoriasis and Lichen Planus [NA]
A ClinicalTrials.gov entry shows withdrawal of a trial investigating Koebner phenomenon in psoriasis and lichen planus.
-
CLINICAL_TRIALS withdrawal · 2026-02-23Clinical Trial Update: Shared Pathways Between Non-Alcoholic Fatty Liver Disease and Psoriatic Disease With Guselekumab Therapy
A clinical trial evaluating guselekumab for shared pathways in psoriasis, psoriatic arthritis, and nonalcoholic fatty liver disease has been…
-
EMA withdrawal · 2025-09-08EMA Withdrawn: Eksunbi (ustekinumab) — Samsung Bioepis NL B.V.
The EMA has withdrawn Eksunbi (ustekinumab) from the European market as of 23 May 2025, affecting indications for Crohn's disease, ulcerativ…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2025-09-04Clinical Trial Update: Safety and Effectiveness of Combined LED Light for the Treatment of Mild to Moderate Plaque Type Psoriasis Vulgaris [NA]
The clinical trial evaluating combined LED light therapy for mild-to-moderate plaque psoriasis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-06-05Clinical Trial Update: A Pilot Study to Explore the Role of Gut Flora in Psoriasis
A pilot study sponsored by ProgenaBiome evaluating the role of gut microbiota in psoriasis has been withdrawn. The withdrawal indicates the …
-
CLINICAL_TRIALS withdrawal · 2025-05-29Clinical Trial Update: Adherence to Otezla [EARLY_Phase 1]
A clinical trial evaluating adherence to Otezla (apremilast) in psoriasis at EARLY_PHASE1 has been withdrawn.
-
EMA withdrawal · 2025-01-06EMA Application withdrawn: Apremilast Viatris (apremilast) — Viatris Limited
The European Medicines Agency has withdrawn Viatris Limited's application for apremilast (Viatris) for the EU market, terminating the market…
-
CLINICAL_TRIALS withdrawal · 2024-05-08Clinical Trial Update: Evaluation of Vitamin D Levels in Psoriasis Patients
A clinical trial evaluating vitamin D levels in psoriasis patients has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2023-03-31Clinical Trial Update: An Efficacy Study of Secukinumab in Plaque Psoriasis Patients With Subclinical Psoriatic Arthritis as Measured by Musculoskeletal Ultrasound [Phase 4]
Phase 4 trial of secukinumab in plaque psoriasis with subclinical psoriatic arthritis was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2022-08-05Clinical Trial Update: Proton Pump Inhibitors Use in Patients With Psoriasis [Phase 4]
A Phase 4 Clinical Trial investigating proton pump inhibitors in patients with psoriasis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2021-07-23Clinical Trial Update: SystemIc iNflammation and Microvascular diSease PreventIon in psoRiatic diseasE [Phase 4]
A Phase 4 clinical trial exploring systemic inflammation and microvascular disease prevention in psoriasis and psoriatic arthritis has been …
-
EMA withdrawal · 2021-01-29EMA Withdrawn: Halimatoz (adalimumab) — Sandoz GmbH
The EMA withdrew Halimatoz (adalimumab) supplied by Sandoz GmbH from the market.
-
EMA withdrawal · 2020-03-25EMA Withdrawn: Kromeya (adalimumab) — Fresenius Kabi Deutschland GmbH
EMA has withdrawn Kromeya (adalimumab) from Fresenius Kabi Deutschland GmbH, effective 2019, affecting multiple inflammatory diseases.
-
EMA withdrawal · 2020-02-20EMA Lapsed: Lifmior (etanercept) — Pfizer Europe MA EEIG
The European Medicines Agency indicates Lifmior (etanercept) has lapsed; the product is no longer active in the market for its indicated con…
-
EMA withdrawal · 2019-03-06EMA Withdrawn: Cyltezo (adalimumab) — Boehringer Ingelheim International GmbH
The EMA withdrew Cyltezo (adalimumab) from Boehringer Ingelheim International GmbH, affecting multiple indications including hidradenitis su…
-
EMA withdrawal · 2019-03-05EMA Withdrawn: Solymbic (adalimumab) — Amgen Europe B.V.
Solymbic (adalimumab) has been withdrawn from the market by Amgen Europe B.V.
-
CLINICAL_TRIALS withdrawal · 2018-07-19Clinical Trial Update: Steroids Added to Dithranol and Narrow Band UVB(Ultraviolet B) (UVBnb) in Psoriasis [Phase 4]
A Phase 4 psoriasis trial evaluating the combination of steroids with dithranol and narrow-band UVB has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2018-03-02Clinical Trial Update: Study of Topical Calcitriol or Oral Calcitriol in Patients With Psoriasis [NA]
This clinical trial update indicates that the study evaluating topical or oral calcitriol for psoriasis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-11-29Clinical Trial Update: A Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of GSK2894512 in Healthy Adult Subjects [Phase 1]
A Phase 1 pharmacokinetic and safety study of GSK2894512 in healthy adult subjects has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-07-17Clinical Trial Update: Psoriatic Arthritis Treated With Liraglutide Therapy: a QUality of Life and Efficacy Study [Phase 2]
This clinical trial update reports that the Phase 2 study evaluating liraglutide for psoriatic arthritis (and related conditions) has been w…
-
CLINICAL_TRIALS withdrawal · 2017-04-20Clinical Trial Update: Assessment of Efficacy and Safety of Secukinumab in Adult Patients in Turkish Population [Phase 3]
Phase 3 trial evaluating secukinumab for psoriasis in adult Turkish patients was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-11-17Clinical Trial Update: Influence of Atorvastatin on Psoriasis Severity and Endothelial Function [Phase 3]
A Phase 3 trial examining atorvastatin for psoriasis severity and endothelial function has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-07-23Clinical Trial Update: Topical Application of AS101 for the Treatment of Psoriasis [Phase 2]
A Phase 2 trial evaluating topical AS101 for mild to moderate psoriasis has been withdrawn.